Crossmark

Comparative Analysis of All-Cause Health Care Resource Utilization and Costs Among Venous Thrombosis Patients Without Cancer Prescribed Apixaban or VKAs in France

Crossref DOI link: https://doi.org/10.1007/s12325-022-02200-7

Published Online: 2022-06-29

Published Print: 2022-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mokgokong, Ruth https://orcid.org/0000-0002-6278-4969
Khachatryan, Artak

Quignot, Nadia

Chaves, Jose

Moniot, Audrey

Gusto, Gaelle
Funding

Funding for this research was provided by:

Pfizer

Bristol-Myers Squibb
License Information

Text and Data Mining valid from 2022-06-29

Version of Record valid from 2022-06-29
More Information

Article History

Received: 12 April 2022

Accepted: 19 May 2022

First Online: 29 June 2022

Document is current

Any future updates will be listed below